RNA標的低分子創薬の世界市場レポート 2025年

RNA標的低分子創薬の市場規模は、今後数年で飛躍的な成長が見込まれます。2029年にはCAGR23.1％で49億2,000万米ドルに成長します。予測期間の成長は、RNAエピジェネティクス調査、RNA-seqと機能ゲノミクス、人工知能（AI）の統合、患者中心のアプローチ、エクソソームを介したドラッグデリバリーの拡大に起因すると考えられます。予測期間における主な動向には、RNA編集技術の出現、CRISPR技術の進歩、技術革新、RNA生物学の進歩、神経変性疾患におけるRNAターゲティングなどがあります。

がん、遺伝性疾患、ウイルス感染の有病率の上昇は、今後数年間におけるRNA標的低分子創薬市場の成長を促進すると予想されます。がんは細胞の制御不能な増殖を特徴とする疾患の集合体であり、ウイルス感染は生物の細胞内で複製するウイルスによって引き起こされます。RNAを標的とした創薬は、これらの病態に対処するために採用されます。これらの病態は、遺伝的要因や機能不全の遺伝物質と関連していることが多く、RNAベースの治療法で標的とすることができるからです。例えば、2024年2月に世界保健機関（WHO）が発表した報告書によると、2022年には世界で約2,000万人のがん患者が新たに発生し、970万人が死亡したと推定されています。最も罹患率が高いのは肺がんで250万人（12.4％）、次いで女性乳がん（230万人、11.6％）、大腸がん（190万人、9.6％）、前立腺がん（150万人、7.3％）、胃がん（97万人、4.9％）となっています。2050年までに、新たながん患者は77％増加し、年間3,500万人を超えると予測されています。したがって、がん、遺伝性疾患、ウイルス感染の有病率の増加が、RNA標的低分子創薬市場の成長を牽引しています。

RNA標的低分子創薬市場の成長には、個別化医療への関心の高まりが拍車をかけています。個別化医療は、医療上の意思決定、介入、薬物療法を個々の患者に合わせるものです。RNAターゲティングの文脈では、個別化された医薬品はより高い特異性を提供し、オフターゲット効果を最小限に抑え、個々の遺伝的変異に対応することができます。STATの報告書によると、2022年10月現在、75,000を超える遺伝子検査製品と300の個別化医薬品が存在しており、ヘルスケアにおける個別化アプローチの重要性が高まっていることを示しています。したがって、個別化医療への関心の高まりは、RNA標的低分子創薬市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のRNA標的低分子創薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のRNA標的低分子創薬市場：成長率分析
• 世界のRNA標的低分子創薬市場の実績：規模と成長, 2019-2024
• 世界のRNA標的低分子創薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界のRNA標的低分子創薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のRNA標的低分子創薬市場：ターゲットRNAタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• メッセンジャーRNA（mRNA）
• ノンコーディングRNA（ncRNA）
• マイクロRNA（miRNA）
• 長鎖ノンコーディングRNA（lncRNA）
• 世界のRNA標的低分子創薬市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリスパーCas9
• RNAアプタマー
• 低分子干渉RNA（siRNA）
• リボザイム
• その他のテクノロジー
• 世界のRNA標的低分子創薬市場：治療領域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 神経学
• 感染症
• 代謝性疾患
• 遺伝性疾患
• その他の治療領域
• 世界のRNA標的低分子創薬市場：デリバリー方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内（IV）
• 経口
• 外用
• その他の方法
• 世界のRNA標的低分子創薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 研究利用
• 治療目的の使用
• 診断用途
• その他の用途
• 世界のRNA標的低分子創薬市場、タイプ別サブセグメンテーション：メッセンジャーRNA（mRNA）、実績と予測, 2019-2024, 2024-2029F, 2034F
• タンパク質コーディングのためのmRNAのターゲット
• mRNA安定性の調整
• mRNA翻訳阻害
• 世界のRNA標的低分子創薬市場、タイプ別サブセグメンテーション：ノンコーディングRNA（ncRNA）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 長鎖ノンコーディングRNA
• 核内低分子RNA
• 核小体低分子RNA
• 世界のRNA標的低分子創薬市場、タイプ別サブセグメンテーション：マイクロRNA（miRNA）、実績と予測, 2019-2024, 2024-2029F, 2034F
• miRNA阻害
• miRNA模倣
• 特定miRNA経路標的
• 世界のRNA標的低分子創薬市場、タイプ別サブセグメンテーション：長鎖ノンコーディングRNA（lncRNA）、実績と予測, 2019-2024, 2024-2029F, 2034F
• lncRNAモジュレーター
• 特定lncRNA機能標的
• lncRNAの治療用途

第7章 地域別・国別分析

• 世界のRNA標的低分子創薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のRNA標的低分子創薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• RNA標的低分子創薬市場：競合情勢
• RNA標的低分子創薬市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Moderna Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• Alnylam Pharmaceuticals Inc.
• Sarepta Therapeutics Inc.
• Evotec A.G.
• PTC Therapeutics Inc.
• Ionis Pharmaceuticals Inc.
• Dicerna Pharmaceuticals Inc.
• Arrakis Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• RNA標的低分子創薬市場2029：新たな機会を提供する国
• RNA標的低分子創薬市場2029：新たな機会を提供するセグメント
• RNA標的低分子創薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

RNA targeting small-molecule drug discovery involves the identification and development of small-molecule drugs designed to interact with RNA molecules, influencing their function or activity. This approach is employed to uncover novel medications for the treatment of diverse diseases, including genetic disorders, viral infections, neurodegenerative conditions, and cancer.

The primary RNA types in the realm of RNA targeting small-molecule drug discovery, are messenger RNA (mRNA), non-coding RNA (ncRNA), microRNA (miRNA), and long non-coding RNA (lncRNA). Messenger RNA (mRNA) serves as the carrier of genetic information from the DNA in the cell's nucleus to the ribosomes, where protein synthesis takes place. Various technologies, such as CRISPR-cas9, RNA aptamers, small interfering RNA (siRNA), ribozymes, and others, are employed across multiple therapeutic areas, including oncology, neurology, infectious diseases, metabolic disorders, genetic conditions, and more. Delivery methods encompass intravenous (IV), oral, topical, and others, with applications in research, therapeutics, diagnostics, and various other uses.

The RNA targeting small molecule drug discovery market research report is one of a series of new reports from The Business Research Company that provides RNA targeting small molecule drug discovery market statistics, including RNA targeting small molecule drug discovery industry global market size, regional shares, competitors with an RNA targeting small molecule drug discovery market share, detailed RNA targeting small molecule drug discovery market segments, market trends, and opportunities, and any further data you may need to thrive in the RNA targeting small molecule drug discovery industry. This RNA-targeting small molecule drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The RNA targeting small molecule drug discovery market size has grown exponentially in recent years. It will grow from $1.76 billion in 2024 to $2.14 billion in 2025 at a compound annual growth rate (CAGR) of 21.8%. The growth in the historic period can be attributed to an increased understanding of disease genetics, genomic and proteomic discoveries, drug resistance challenges, investment in biotechnology and pharmaceutical research, rise of RNA therapeutics

The RNA targeting small molecule drug discovery market size is expected to see exponential growth in the next few years. It will grow to $4.92 billion in 2029 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to the expansion of RNA epigenetics research, RNA-seq and functional genomics, integration of artificial intelligence (AI), patient-centric approaches, and exosome-mediated drug delivery. Major trends in the forecast period include the emergence of RNA editing technologies, advancements in CRISPR technology, technological innovations, advancements in RNA biology, and RNA targeting in neurodegenerative diseases.

The rising prevalence of cancer, genetic disorders, and viral infections is expected to propel the growth of the RNA-targeted small-molecule drug discovery market in the coming years. Cancer is a collection of diseases characterized by the uncontrolled growth of cells, while viral infections are caused by viruses that replicate within the cells of living organisms. RNA-targeting drug discovery is employed to address these conditions, as they are often linked to genetic factors and malfunctioning genetic material, which can be targeted with RNA-based therapies. For example, in February 2024, a report from the World Health Organization (WHO) estimated that there were approximately 20 million new cancer cases and 9.7 million deaths globally in 2022. Lung cancer was the most prevalent, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, new cancer cases are projected to rise by 77%, exceeding 35 million annually. Therefore, the increasing prevalence of cancer, genetic disorders, and viral infections is driving the growth of the RNA-targeted small-molecule drug discovery market.

The growth of the RNA-targeted small-molecule drug discovery market is fueled by the rising interest in personalized medicine. Personalized medicine tailors medical decisions, interventions, and drug therapies to individual patients. In the context of RNA targeting, personalized medicines can offer higher specificity, minimizing off-target effects and catering to individual genetic variations. A report by STAT indicates over 75,000 genetic testing products and 300 personalized medicines in existence as of October 2022, underscoring the increasing emphasis on personalized approaches in healthcare. Hence, the surge in personalized medicine interest contributes to the expansion of the RNA-targeted small-molecule drug discovery market.

The integration of artificial intelligence (AI) into drug discovery processes is a prominent trend in the small-molecule drug discovery market. Major companies within the market are embracing AI technology to expedite drug discovery procedures and maintain their competitive positions. For example, in May 2023, Google Cloud, the cloud computing suite of the US-based technology company Google, introduced the Target and Lead Identification Suite and Multiomics Suite to streamline drug discovery. The Multiomics Suite facilitates the identification and analysis of genetic data, aiding in the design of precision medicines. The Target and Lead Identification Suite supports researchers in comprehending the role of amino acids and predicting protein structures.

Companies in the RNA-targeting small-molecule drug discovery market are innovating by developing platforms such as software-as-a-service (SaaS) to enhance their competitiveness. SaaS is a software distribution model where applications are hosted by a third-party provider and made accessible to customers over the internet. In December 2023, Merck & Co. Inc., a US-based science and technology company, launched AIDDISON, a platform that recommends optimal ways to synthesize selected medications. This AI-driven approach aims to bring significant cost savings to the drug discovery process and improve the success rate of introducing novel medicines. AIDDISON integrates computer-aided drug design, machine learning, and generative AI to accelerate medication development by extracting insights from large datasets.

In September 2022, Gilead Sciences, a US-based biopharmaceutical company, acquired MiroBio for $405 million. This acquisition allows Gilead to access MiroBio's proprietary discovery platform, along with its entire portfolio of immune inhibitory receptor agonists. MiroBio is a UK-based biotechnology company focused on developing RNA-targeted therapeutics.

Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics

North America was the largest region in the RNA targeting small molecule drug discovery market in 2024. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the rna targeting small molecule drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The RNA targeting small molecule drug discovery market consists of revenues earned by entities by providing hit identification, hit validation, and hit characterization. The market value includes the value of related goods sold by the service provider or included within the service offering. The RNA targeting small molecule drug discovery market also includes sales of asRNAs, and siRNAs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

RNA Targeting Small Molecule Drug Discovery Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rna targeting small molecule drug discovery market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rna targeting small molecule drug discovery ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rna targeting small molecule drug discovery market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Target RNA Type: Messenger RNA (mRNA); Non-Coding RNA (ncRNA); MicroRNA (miRNA); Long Non-Coding RNA (lncRNA)
• 2) By Technology: CRISPR-Cas9; RNA Aptamers; Small Interfering RNA (siRNA); Ribozymes; Other Technologies
• 3) By Therapeutic Area: Oncology; Neurology; Infectious Disease; Metabolic Diseases; Genetic Disorders; Other Therapeutic Areas
• 4) By Delivery Method: Intravenous (IV); Oral; Topical; Other Methods
• 5) By Application: Research Use; Therapeutic Use; Diagnostic Use; Other Applications
• Subsegments:
• 1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding; Modulation Of mRNA Stability; mRNA Translation Inhibition
• 2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA; Small Nuclear RNA; Small Nucleolar RNA
• 3) By MicroRNA (miRNA): miRNA Inhibition; miRNA Mimics; Targeting Specific miRNA Pathways
• 4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators; Targeting Specific lncRNA Functions; Therapeutic Applications Of lncRNA
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Merck & Co. Inc; Bayer AG; Novartis AG; Sanofi SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. RNA Targeting Small Molecule Drug Discovery Market Characteristics

3. RNA Targeting Small Molecule Drug Discovery Market Trends And Strategies

4. RNA Targeting Small Molecule Drug Discovery Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global RNA Targeting Small Molecule Drug Discovery Growth Analysis And Strategic Analysis Framework

• 5.1. Global RNA Targeting Small Molecule Drug Discovery PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global RNA Targeting Small Molecule Drug Discovery Market Growth Rate Analysis
• 5.4. Global RNA Targeting Small Molecule Drug Discovery Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global RNA Targeting Small Molecule Drug Discovery Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global RNA Targeting Small Molecule Drug Discovery Total Addressable Market (TAM)

6. RNA Targeting Small Molecule Drug Discovery Market Segmentation

• 6.1. Global RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Messenger RNA (mRNA)
• Non-Coding RNA (ncRNA)
• MicroRNA (miRNA)
• Long Non-Coding RNA (lncRNA)
• 6.2. Global RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CRISPR-Cas9
• RNA Aptamers
• Small Interfering RNA (siRNA)
• Ribozymes
• Other Technologies
• 6.3. Global RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Neurology
• Infectious Disease
• Metabolic Diseases
• Genetic Disorders
• Other Therapeutic Areas
• 6.4. Global RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV)
• Oral
• Topical
• Other Methods
• 6.5. Global RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Research Use
• Therapeutic Use
• Diagnostic Use
• Other Applications
• 6.6. Global RNA Targeting Small Molecule Drug Discovery Market, Sub-Segmentation Of Messenger RNA (mRNA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeting mRNA For Protein Coding
• Modulation Of mRNA Stability
• mRNA Translation Inhibition
• 6.7. Global RNA Targeting Small Molecule Drug Discovery Market, Sub-Segmentation Of Non-Coding RNA (ncRNA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Long Non-Coding RNA
• Small Nuclear RNA
• Small Nucleolar RNA
• 6.8. Global RNA Targeting Small Molecule Drug Discovery Market, Sub-Segmentation Of MicroRNA (miRNA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• miRNA Inhibition
• miRNA Mimics
• Targeting Specific miRNA Pathways
• 6.9. Global RNA Targeting Small Molecule Drug Discovery Market, Sub-Segmentation Of Long Non-Coding RNA (lncRNA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• lncRNA Modulators
• Targeting Specific lncRNA Functions
• Therapeutic Applications Of lncRNA

7. RNA Targeting Small Molecule Drug Discovery Market Regional And Country Analysis

• 7.1. Global RNA Targeting Small Molecule Drug Discovery Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global RNA Targeting Small Molecule Drug Discovery Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific RNA Targeting Small Molecule Drug Discovery Market

• 8.1. Asia-Pacific RNA Targeting Small Molecule Drug Discovery Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China RNA Targeting Small Molecule Drug Discovery Market

• 9.1. China RNA Targeting Small Molecule Drug Discovery Market Overview
• 9.2. China RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India RNA Targeting Small Molecule Drug Discovery Market

• 10.1. India RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan RNA Targeting Small Molecule Drug Discovery Market

• 11.1. Japan RNA Targeting Small Molecule Drug Discovery Market Overview
• 11.2. Japan RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia RNA Targeting Small Molecule Drug Discovery Market

• 12.1. Australia RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia RNA Targeting Small Molecule Drug Discovery Market

• 13.1. Indonesia RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea RNA Targeting Small Molecule Drug Discovery Market

• 14.1. South Korea RNA Targeting Small Molecule Drug Discovery Market Overview
• 14.2. South Korea RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe RNA Targeting Small Molecule Drug Discovery Market

• 15.1. Western Europe RNA Targeting Small Molecule Drug Discovery Market Overview
• 15.2. Western Europe RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK RNA Targeting Small Molecule Drug Discovery Market

• 16.1. UK RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany RNA Targeting Small Molecule Drug Discovery Market

• 17.1. Germany RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France RNA Targeting Small Molecule Drug Discovery Market

• 18.1. France RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy RNA Targeting Small Molecule Drug Discovery Market

• 19.1. Italy RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain RNA Targeting Small Molecule Drug Discovery Market

• 20.1. Spain RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe RNA Targeting Small Molecule Drug Discovery Market

• 21.1. Eastern Europe RNA Targeting Small Molecule Drug Discovery Market Overview
• 21.2. Eastern Europe RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia RNA Targeting Small Molecule Drug Discovery Market

• 22.1. Russia RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America RNA Targeting Small Molecule Drug Discovery Market

• 23.1. North America RNA Targeting Small Molecule Drug Discovery Market Overview
• 23.2. North America RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA RNA Targeting Small Molecule Drug Discovery Market

• 24.1. USA RNA Targeting Small Molecule Drug Discovery Market Overview
• 24.2. USA RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada RNA Targeting Small Molecule Drug Discovery Market

• 25.1. Canada RNA Targeting Small Molecule Drug Discovery Market Overview
• 25.2. Canada RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America RNA Targeting Small Molecule Drug Discovery Market

• 26.1. South America RNA Targeting Small Molecule Drug Discovery Market Overview
• 26.2. South America RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil RNA Targeting Small Molecule Drug Discovery Market

• 27.1. Brazil RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East RNA Targeting Small Molecule Drug Discovery Market

• 28.1. Middle East RNA Targeting Small Molecule Drug Discovery Market Overview
• 28.2. Middle East RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa RNA Targeting Small Molecule Drug Discovery Market

• 29.1. Africa RNA Targeting Small Molecule Drug Discovery Market Overview
• 29.2. Africa RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Target RNA Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa RNA Targeting Small Molecule Drug Discovery Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. RNA Targeting Small Molecule Drug Discovery Market Competitive Landscape And Company Profiles

• 30.1. RNA Targeting Small Molecule Drug Discovery Market Competitive Landscape
• 30.2. RNA Targeting Small Molecule Drug Discovery Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. RNA Targeting Small Molecule Drug Discovery Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca PLC
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Moderna Inc.
• 31.7. Astellas Pharma Inc.
• 31.8. Biogen Inc.
• 31.9. Alnylam Pharmaceuticals Inc.
• 31.10. Sarepta Therapeutics Inc.
• 31.11. Evotec A.G.
• 31.12. PTC Therapeutics Inc.
• 31.13. Ionis Pharmaceuticals Inc.
• 31.14. Dicerna Pharmaceuticals Inc.
• 31.15. Arrakis Therapeutics

32. Global RNA Targeting Small Molecule Drug Discovery Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The RNA Targeting Small Molecule Drug Discovery Market

34. Recent Developments In The RNA Targeting Small Molecule Drug Discovery Market

35. RNA Targeting Small Molecule Drug Discovery Market High Potential Countries, Segments and Strategies

• 35.1 RNA Targeting Small Molecule Drug Discovery Market In 2029 - Countries Offering Most New Opportunities
• 35.2 RNA Targeting Small Molecule Drug Discovery Market In 2029 - Segments Offering Most New Opportunities
• 35.3 RNA Targeting Small Molecule Drug Discovery Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer